Skip to main content

Interim Results 30 June 2019

17 September, 2019
  • EBITDA3 increase of 119%, from €10.0m to €21.9m.
  • Adjusted EPS of 9.3 cent representing 157% year on year growth.
  • Net bank debt of €161.0m, before gross IPO proceeds which completed on 17 July 2019 raising €139.4m.
  • Return on capital employed for the period was 14.3%.

Strategic and Operational Highlights

  • Strong gross profit growth across all 3 trading divisions, with 7% organic growth.
  • 52% of gross profit from Growth Divisions: Commercial & Clinical and Product Access.    
  • IPO Complete: successful dual listing on 17 July 2019 on the Euronext Growth and AIM markets.
  • Durbin Acquisition: key strategic acquisition of Durbin completed 31 July 20194.    
  • Geographic Growth: 60% of organic growth in growth divisions from UK and Europe.

Download Interim Results Here

Download Interim Presentation Here